Description

Forigerimod TFA (CAS No. 2417491-82-6), also known as IPP-201101 TFA, is a synthetic 21-amino-acid peptide fragment derived from the U1 small nuclear ribonucleoprotein 70 kDa (U1-70K). Specifically, it is a phosphorylated derivative at Ser140. This modification enhances its stability and immunomodulatory properties, making it a potent CD4 T-cell modulator.

In preclinical studies, Forigerimod TFA has demonstrated the ability to inhibit autophagy and modulate immune responses, particularly in the context of autoimmune disorders. It has been investigated for its potential therapeutic effects in systemic lupus erythematosus (SLE), a chronic autoimmune disease characterized by widespread inflammation and tissue damage.

Manufactured under GMP standards with a purity of 99.88%, Forigerimod TFA ensures consistency and reliability for experimental use.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action:
Forigerimod TFA functions by modulating CD4 T-cell responses through its interaction with the U1-70K protein. The phosphorylated peptide fragment influences T-cell activation and differentiation, leading to altered immune responses. In preclinical models, Forigerimod TFA has been shown to inhibit autophagy, a process involved in immune cell regulation.

Research Applications:

• Systemic Lupus Erythematosus (SLE): Investigating the modulation of immune responses to alleviate disease symptoms.

• Autoimmune Disorder Research: Exploring the potential of Forigerimod TFA in other autoimmune conditions characterized by T-cell dysregulation.

  

Side Effects (Research Context Only)

Forigerimod TFA is intended for laboratory research use only. In preclinical studies, it has been shown to modulate immune responses without significant adverse effects. However, as with all experimental compounds, appropriate safety protocols should be followed during handling and administration.

Disclaimer

 is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic purposes. Users should adhere to institutional safety guidelines and regulatory requirements when handling this compound.